GlycoMimetics grants performance-based stock options to NEOs vesting on FDA approval of uproleselan

CRESCENT BIOPHARMA, INC.

CEO Harout Semerjian granted 521,250 shares; CFO Brian Hahn and CMO Edwin Rock each granted 187,500 shares.
Options have exercise price of $0.2589 per share and vest upon FDA approval of uproleselan for AML.
Awards are in addition to service-based options granted Jan 12, 2024 with exercise price of $3.11 per share.
Vesting is contingent on continued service through the FDA approval date.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.